Tag Archives: biologic

Biologics by McKesson Expands Specialty Pharmacy Oncology Offerings

Biologics, as part of a recent reorganization, is now joining McKesson’s Provider Solutions business within the Pharmaceutical Solutions and Services (PSaS) business unit

AllianceRx Walgreens Prime Offers a Patented Cold-Chain Shipment Packaging Process

A new patented process for delivering specialty medicine will assure AllianceRx Walgreens Prime patients receive their medicine delivered at the correct temperature

Oncology Biosimilars: Opportunity or Not?

Oncology Biosimilars: Opportunity or Not? VBCC – April 2016, Vol 7, No 3 – Employers’ Perspective F. Randy Vogenberg, PhD, RPh, Partner Access Market Intelligence Martha M. Rumore, PharmD, JD, MS, LLM, FAPhA The United States has the largest biologic drugs market and high prices for biologics, such as monoclonal antibodies, therapeutic proteins, immunomodulators, and […]

Impact of Commercial Insurance in 2017

Clinical trial collaborations – an idea whose time has come

Impact of Commercial Insurance in 2017 – Considerable attention and planning has been focused on the Medicare market, but as we see from the chart below, Medicare represents approximately 13% of the total population.   Employer 49% Medicaid 19% Medicare 13% Uninsured 10% Non-Group 6% Other Public 2% (Source: Kaiser Family Foundation) A recent Mercer […]

Specialty Drug Spend Under the Medical Benefit

Continuation in rising costs of specialty drugs and maybe accelerate in next 1-2 years: Randy Vogenberg

Specialty Drug Spend Under the Medical Benefit — Biologic, biotechnology based, rare disease or high cost pharmaceuticals—collectively known as specialty drugs—can be covered under the pharmacy benefit, the medical benefit, or both depending on the plan sponsors’ benefit design required of the payor. On average, up to 50% of specialty drugs are covered under the […]

Oncology Care Marketing Increasing

Knowsource.com Announces Transition to Access Market Intelligence

Oncology care marketing increasing in the U.S. marketplace. However, continuing benefit coverage planning for 2017 are also topics that are receiving increasing attention—to include cancer care. Just as the new oncology product pipeline is providing new options or treatments for a wide variety of cancers, market stakeholders are continuing to adjust their daily practices around providing […]

Biosimilar Confusion and Insights

Since Virginia became the first state in May 2013 to enact legislation regulating a pharmacist’s substitution of an interchangeable biologic drug for a prescribed reference biologic drug, there has not been much activity or clarity on the issue. This issue continues to pit manufacturer versus manufacturer, and other stakeholders against each other in the policy […]